SCHEMBL8937235

SCHEMBL8937235

CCCOc1ccc(C(=CC(=O)O)c2ccc(Cl)c(Cl)c2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.46
PLK1 P53350 1/20 0.46
DPP4 P27487 1/20 0.44
ALDH1A1 P00352 5/20 0.44
LMNA P02545 3/20 0.44
KDM4E B2RXH2 1/20 0.44
CYP1A2 P05177 1/20 0.43
CYP2C19 P33261 1/20 0.43
TP53 P04637 3/20 0.43
TSHR P16473 1/20 0.43
FFAR1 O14842 1/20 0.42
MAPT P10636 2/20 0.42
NPC1 O15118 1/20 0.42
NFKB1 P19838 1/20 0.42
CASP3 P42574 1/20 0.42
RAB9A P51151 1/20 0.42
NFKB2 Q00653 1/20 0.42
RELA Q04206 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8937229 1.00 L3MBTL1 (0.46) L3MBTL1PLK1DPP4ALDH1A1LMNA
SCHEMBL8937232 1.00 L3MBTL1 (0.46) L3MBTL1PLK1DPP4ALDH1A1LMNA
SCHEMBL8937343 0.87 NPC1 (0.54) L3MBTL1PLK1ALDH1A1LMNATP53
SCHEMBL8937347 0.87 NPC1 (0.54) L3MBTL1PLK1ALDH1A1LMNATP53
SCHEMBL8937346 0.87 NPC1 (0.54) L3MBTL1PLK1ALDH1A1LMNATP53
SCHEMBL8937615 0.85 MAPT (0.60) L3MBTL1PLK1ALDH1A1LMNATP53
SCHEMBL8937565 0.85 MAPT (0.60) L3MBTL1PLK1ALDH1A1LMNATP53
SCHEMBL8937571 0.85 MAPT (0.60) L3MBTL1PLK1ALDH1A1LMNATP53
SCHEMBL8937234 0.82 CA1 (0.46) ALDH1A1LMNAKDM4ETP53TSHR
SCHEMBL8937239 0.82 CA1 (0.46) ALDH1A1LMNAKDM4ETP53TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5559109-A Method of treating a PAF-mediated pathology or for treating or preventing psoriasis, nephritis, asthma or shock by administering a PAF antagonist SANKKO COMPANY, LIMITED (JP) 1996-09-24 US disclosed
US-5556852-A PLATELET ACTIVATING FACTOR ANTAGONISTS SANKYO COMPANY, LIMITED (JP) 1996-09-17 US disclosed
EP-0395446-B1 N-acryloylpiperazine derivatives, their preparation and their use as paf antagonists SANKYO CO (JP) 1995-03-01 EP disclosed
US-5369106-A N-acryloylpiperazine derivatives, their preparation and their use of PAF antagonists SANKYO COMPANY, LIMITED (JP) 1994-11-29 US disclosed
US-5192766-A Platelet activating factor antagonist SANKYO COMPANY, LIMITED (JP) 1993-03-09 US disclosed
EP-0395446-A2 N-acryloylpiperazine derivatives, their preparation and their use as paf antagonists Sankyo Company Limited (JP) 1990-10-31 EP disclosed